We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.40 | 2.30 | 2.50 | 2.40 | 2.40 | 2.40 | 14,156 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0095 | -2.53 | 13.04M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/11/2024 08:31 | Beeks got sucked in too during the last pump and dump. That serves him right for ignoring the red flags. | batiatus | |
11/11/2024 08:31 | This is pretty compelling....surely 'Genedrive featured in UK Government Department for Business and Trade spotlight on UK genomics genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that it has been featured in the UK Government Department for Business and Trade ("DBT") publication "UK Genomics Spotlight 2024: Celebrating success and looking ahead" The document is available at The report highlights the UK's depth and breadth of expertise for export as world leaders in the field of genomics, as well as opportunities for investing in the UK. It describes the ecosystem which has enabled the delivery of genomic medicine in the UK and expertise in various national initiatives and programmes which are contributing to the genomics landscape of the future. The DBT has produced the Genomics Spotlight 2024 to showcase the UK's expertise in genomics and latest developments that make the UK a hub for genomics business and investment, and has worked closely with the NHS, including NHS England and all three of the devolved nations, as well as encouraging input from several key organisations and companies in the UK.' | hazl | |
11/11/2024 08:29 | I leave the bb for less than a week and miss the great announcement on the 5th! I can't believe the naysayers have been given cart blanche here. | hazl | |
11/11/2024 08:21 | Plenty of us here, we just don't want converse with a bonehead like you. | premium beeks | |
11/11/2024 08:19 | Everyone have left the party except bones. The rampers have quietly sold. They all knew this was a pump and dump. Bones the Muppet were sucked in and abandoned from his so-called mates. Too late for him to realise lol. | batiatus | |
10/11/2024 10:37 | Will it be another week ahead without sales? It's sure looking that way SP to drop back to sub 2p? | batiatus | |
08/11/2024 17:58 | How many kits have GDR sold this month? Answer is 0. What is the company monthly expense? Answer is £400-600K | batiatus | |
08/11/2024 15:29 | GEORGINA ENERGY [GEX] MAIN MARKET STOCK 🚀 BOOM!!!!! AND YET ANOTHER X POST @ 1.36pm today 🚀 #GEX Hussar: "Preliminary site visit scheduled for Nov 24-27 with traditional landowners & environmental consultants, vital for securing our drilling application with DEMIRS. Resource upgrade and seismic reprocessing are underway for guaranteed December start!!! #GEX #Energy Absolutely EVERYTHING is in place and the CEO has £3 million of own cash involved Guaranteed drill!!!!! *NT to buy @ 9.40p* 8% up and nearly 20% in 2 days from the lows This was a 12.5p RTO & PIs paid 19.40p back early August | neilll77 | |
08/11/2024 12:16 | Two more for the bin | petersinthemarket | |
08/11/2024 07:29 | POLX about to break out above 2p. I see it as a steal for the FDA approvedXenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.65p and gap at over 3p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations. Similar set up to GDR before it filled it's gap. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR. | m_night10 | |
07/11/2024 16:18 | How is everyone doing? Still believe in the GDR 10p target? You do know the company is struggling to sell right? And the monthly cash burn is £400-600K. (G)enuinely (D)on't (R)ecommend | batiatus | |
07/11/2024 15:48 | A new post 5 minutes ago from the official Georgina Energy [GEX] X PAGE #GEX Update: We’re fully funded & advancing across our portfolio. With Hussar drilling set for December and progress at Mt Winter, we are on track for major milestones in the coming weeks. See our recent Operational Update below👇 Looks set to blow over at GEX. NT @ 8.87p... IPO was 12.50p and CEO has millions of own cash invested AND the Distressed seller Premier Milton have fully sold!!!! hxxps://x.com/Georgi Debs Xxxx | neilll77 | |
06/11/2024 09:40 | If the company has news then release it don't hold back. But they can't because no one is buying their kits, no sales. Bones is losing money. He doesn't understand the word profit. | batiatus | |
05/11/2024 23:05 | What tour hearing ,don't make me laugh like your some kind of in the know person . | bones698 | |
05/11/2024 16:15 | Yes Kingston, serious cash is leaving the UK stock market, or at least that's what I am hearing of late. Like you say, there is nothing to stimulate growth. Expect the UK stock market to be battered into 2025. | batiatus | |
05/11/2024 15:58 | We are now into November. It gets dark early. Winter is coming. The general economy is in bad shape. Huge tax increases have infuriated many people, especially when the Labour government has twisted the narrative of its manifesto to say that there would be no taxes on the working people. Huge expenditure is welcome but in the wrong sectors. The budget does not stimulate the econony. Politics and ideology aside, whilst we have been talking about whether to build the third runway at London Heathrow Airport China has built many new airports, 6,000 miles of new roads and 6,000 miles of high speed rail every year for the last 20 years. 6 G is coming to China whilst we have not really installed 5 G yet. The London mayor had promised to install wifi throughout the London Underground by the end of 2024 the Shanghai metro network had already been installed with 5G in 2020. I am therefore not surprised to hear that Chinese political scientists criticise Western leaders as middle managers who keep things crawling along ineffectively. I am still waiting for the day when a British team of workers to build a new hospital in ten days. | kingston78 | |
05/11/2024 15:40 | These guys will never make any profits, or that what it seems judging by past performance and the current evidence. Remember they missed the golden opportunity for the COVID test kits? Now they are struggling to sell the stroke kit. Was watching the BBC news yesterday, they talked about increase in number of strokes in the UK and it's affecting younger age groups, but no where did it mention the GDR test kit. What we know for sure is: - monthly cash burn of £400-600K - £100K sales or 1,250 kits sold so far - Cash in the bank is under £5 million So far, evidence suggests lack of interests in the kits. Otherwise orders would be flying in already. FDA is still a speculation. The BOD at GDR are moving at snail pace. Exhibition booth in December (I think), which translate to the company has only just begun to think about promoting their product. If they had received large response they wouldn't be promoting further. Not enough sales to break even and cash is running out fast, I can only assume another raise by 2025? | batiatus | |
05/11/2024 15:04 | Who got shaken out? Buy back before it takes out 3p | atmysignal | |
05/11/2024 13:07 | As previously pointed out by some posters here that even if there were many sales orders by the NHS, the company would still lose a lot of money because revenue would be well below expenditure. No matter whichever way you analyse it GDR will have to raise further funds next year, probably as early as March 2025. Its share price will drift lower despite repeated attempts to ramp it up. This is a sad fact of business generally. Many good companies don't survive the economic reality. | kingston78 | |
05/11/2024 12:46 | Another tree shake to loosen some holders. | daddy warbucks | |
05/11/2024 12:15 | Alowing for the stupidly of the NHS no. | petersmith6 | |
05/11/2024 11:56 | "Genedrive featured in UK Government Department for Business and Trade spotlight on UK genomics"It would be very strange to highlight our company to overseas buyers and then not use it in the UK, wouldn't you think? | daddy warbucks | |
05/11/2024 11:52 | Bones and beeks are examples of greedy traders ignoring the the facts presented to them. Hence they are locked in having bought at a higher price in the last pump and dump. Now these two low lifes are taking their frustrations out onto others. They have neither the intelligence or emotional qualities to be a good trader. | batiatus | |
05/11/2024 11:00 | Hence why we should forget the UK and target America.. there health care system if run by share holders and lawyers.. | petersmith6 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions